A citation-based method for searching scientific literature

Barzin Y Nabet, Mohammad S Esfahani, Everett J Moding, Emily G Hamilton, Jacob J Chabon, Hira Rizvi, Chloe B Steen, Aadel A Chaudhuri, Chih Long Liu, Angela B Hui, Diego Almanza, Henning Stehr, Linda Gojenola, Rene F Bonilla, Michael C Jin, Young-Jun Jeon, Diane Tseng, Cailian Liu, Taha Merghoub, Joel W Neal, Heather A Wakelee, Sukhmani K Padda, Kavitha J Ramchandran, Millie Das, Andrew J Plodkowski, Christopher Yoo, Emily L Chen, Ryan B Ko, Aaron M Newman, Matthew D Hellmann, Ash A Alizadeh, Maximilian Diehn. Cell 2020
Times Cited: 45







List of co-cited articles
377 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
David R Gandara, Sarah M Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff Otto, Christine Malboeuf,[...]. Nat Med 2018
485
26

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Luis Paz-Ares, Reyes Bernabe Caro, Bogdan Zurawski, Sang-We Kim, Enric Carcereny Costa, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez,[...]. N Engl J Med 2019
666
22

Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Valsamo Anagnostou, Patrick M Forde, James R White, Noushin Niknafs, Carolyn Hruban, Jarushka Naidoo, Kristen Marrone, I K Ashok Sivakumar, Daniel C Bruhm, Samuel Rosner,[...]. Cancer Res 2019
89
22

Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade.
Qu Zhang, Jia Luo, Song Wu, Han Si, Chen Gao, Wenjing Xu, Shaad E Abdullah, Brandon W Higgs, Phillip A Dennis, Michiel S van der Heijden,[...]. Cancer Discov 2020
38
26

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Leena Gandhi, Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis, Manuel Domine, Philip Clingan, Maximilian J Hochmair, Steven F Powell,[...]. N Engl J Med 2018
20


Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.
Christopher Abbosh, Nicolai J Birkbak, Gareth A Wilson, Mariam Jamal-Hanjani, Tudor Constantin, Raheleh Salari, John Le Quesne, David A Moore, Selvaraju Veeriah, Rachel Rosenthal,[...]. Nature 2017
641
17

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Zhijie Wang, Jianchun Duan, Shangli Cai, Miao Han, Hua Dong, Jun Zhao, Bo Zhu, Shuhang Wang, Minglei Zhuo, Jianguo Sun,[...]. JAMA Oncol 2019
175
15

PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Paul C Tumeh, Christina L Harview, Jennifer H Yearley, I Peter Shintaku, Emma J M Taylor, Lidia Robert, Bartosz Chmielowski, Marko Spasic, Gina Henry, Voicu Ciobanu,[...]. Nature 2014
15

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Tony S K Mok, Yi-Long Wu, Iveta Kudaba, Dariusz M Kowalski, Byoung Chul Cho, Hande Z Turna, Gilberto Castro, Vichien Srimuninnimit, Konstantin K Laktionov, Igor Bondarenko,[...]. Lancet 2019
973
15

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Naiyer A Rizvi, Byoung Chul Cho, Niels Reinmuth, Ki Hyeong Lee, Alexander Luft, Myung-Ju Ahn, Michel M van den Heuvel, Manuel Cobo, David Vicente, Alexey Smolin,[...]. JAMA Oncol 2020
128
15

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, Alexandra Snyder, Pia Kvistborg, Vladimir Makarov, Jonathan J Havel, William Lee, Jianda Yuan, Phillip Wong, Teresa S Ho,[...]. Science 2015
13

Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.
Aadel A Chaudhuri, Jacob J Chabon, Alexander F Lovejoy, Aaron M Newman, Henning Stehr, Tej D Azad, Michael S Khodadoust, Mohammad Shahrokh Esfahani, Chih Long Liu, Li Zhou,[...]. Cancer Discov 2017
287
13

Genome-wide cell-free DNA fragmentation in patients with cancer.
Stephen Cristiano, Alessandro Leal, Jillian Phallen, Jacob Fiksel, Vilmos Adleff, Daniel C Bruhm, Sarah Østrup Jensen, Jamie E Medina, Carolyn Hruban, James R White,[...]. Nature 2019
224
13

Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
Sarah B Goldberg, Azeet Narayan, Adam J Kole, Roy H Decker, Jimmitti Teysir, Nicholas J Carriero, Angela Lee, Roxanne Nemati, Sameer K Nath, Shrikant M Mane,[...]. Clin Cancer Res 2018
138
13

The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors.
Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Jaekyung Cheon, Young Joo Min, Su-Hyung Park,[...]. Clin Cancer Res 2019
54
13

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. J Clin Oncol 2019
487
13

Sensitive tumour detection and classification using plasma cell-free DNA methylomes.
Shu Yi Shen, Rajat Singhania, Gordon Fehringer, Ankur Chakravarthy, Michael H A Roehrl, Dianne Chadwick, Philip C Zuzarte, Ayelet Borgida, Ting Ting Wang, Tiantian Li,[...]. Nature 2018
244
13

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
Jeanne Tie, Yuxuan Wang, Cristian Tomasetti, Lu Li, Simeon Springer, Isaac Kinde, Natalie Silliman, Mark Tacey, Hui-Li Wong, Michael Christie,[...]. Sci Transl Med 2016
572
13

High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Pedram Razavi, Bob T Li, David N Brown, Byoungsok Jung, Earl Hubbell, Ronglai Shen, Wassim Abida, Krishna Juluru, Ino De Bruijn, Chenlu Hou,[...]. Nat Med 2019
185
13

Detection and localization of surgically resectable cancers with a multi-analyte blood test.
Joshua D Cohen, Lu Li, Yuxuan Wang, Christopher Thoburn, Bahman Afsari, Ludmila Danilova, Christopher Douville, Ammar A Javed, Fay Wong, Austin Mattox,[...]. Science 2018
928
13

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
11

Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy.
Roberto Ferrara, Marie Naigeon, Edouard Auclin, Boris Duchemann, Lydie Cassard, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Aude Desnoyer, Laura Mezquita,[...]. Clin Cancer Res 2021
15
33

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Nicolas Guibert, Myriam Delaunay, Amélie Lusque, Nadia Boubekeur, Isabelle Rouquette, Estelle Clermont, Jean Mourlanette, Sandrine Gouin, Inge Dormoy, Gilles Favre,[...]. Lung Cancer 2018
89
11

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L Topalian, F Stephen Hodi, Julie R Brahmer, Scott N Gettinger, David C Smith, David F McDermott, John D Powderly, Richard D Carvajal, Jeffrey A Sosman, Michael B Atkins,[...]. N Engl J Med 2012
11

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman,[...]. N Engl J Med 2018
11

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.
Menno Tamminga, Sanne de Wit, T Jeroen N Hiltermann, Wim Timens, Ed Schuuring, Leon W M M Terstappen, Harry J M Groen. J Immunother Cancer 2019
29
17

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.
M F Sanmamed, J L Perez-Gracia, K A Schalper, J P Fusco, A Gonzalez, M E Rodriguez-Ruiz, C Oñate, G Perez, C Alfaro, S Martín-Algarra,[...]. Ann Oncol 2017
160
11

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
11

Top 10 Challenges in Cancer Immunotherapy.
Priti S Hegde, Daniel S Chen. Immunity 2020
257
11

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Roy S Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, Alain Vergnenegre, Carlos H Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andric, Sarayut Geater,[...]. N Engl J Med 2020
150
11

Detection of circulating tumor DNA in early- and late-stage human malignancies.
Chetan Bettegowda, Mark Sausen, Rebecca J Leary, Isaac Kinde, Yuxuan Wang, Nishant Agrawal, Bjarne R Bartlett, Hao Wang, Brandon Luber, Rhoda M Alani,[...]. Sci Transl Med 2014
11

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC.
Christian Rolfo, Philip C Mack, Giorgio V Scagliotti, Paul Baas, Fabrice Barlesi, Trever G Bivona, Roy S Herbst, Tony S Mok, Nir Peled, Robert Pirker,[...]. J Thorac Oncol 2018
261
11

Integrating genomic features for non-invasive early lung cancer detection.
Jacob J Chabon, Emily G Hamilton, David M Kurtz, Mohammad S Esfahani, Everett J Moding, Henning Stehr, Joseph Schroers-Martin, Barzin Y Nabet, Binbin Chen, Aadel A Chaudhuri,[...]. Nature 2020
76
11

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
Charu Aggarwal, Jeffrey C Thompson, Taylor A Black, Sharyn I Katz, Ryan Fan, Stephanie S Yee, Austin L Chien, Tracey L Evans, Joshua M Bauml, Evan W Alley,[...]. JAMA Oncol 2019
143
11

Circulating mutant DNA to assess tumor dynamics.
Frank Diehl, Kerstin Schmidt, Michael A Choti, Katharine Romans, Steven Goodman, Meng Li, Katherine Thornton, Nishant Agrawal, Lori Sokoll, Steve A Szabo,[...]. Nat Med 2008
11

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.
Aaron M Newman, Scott V Bratman, Jacqueline To, Jacob F Wynne, Neville C W Eclov, Leslie A Modlin, Chih Long Liu, Joel W Neal, Heather A Wakelee, Robert E Merritt,[...]. Nat Med 2014
11

Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.
Everett J Moding, Yufei Liu, Barzin Y Nabet, Jacob J Chabon, Aadel A Chaudhuri, Angela B Hui, Rene F Bonilla, Ryan B Ko, Christopher H Yoo, Linda Gojenola,[...]. Nat Cancer 2020
13
38

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Luis Paz-Ares, Alexander Luft, David Vicente, Ali Tafreshi, Mahmut Gümüş, Julien Mazières, Barbara Hermes, Filiz Çay Şenler, Tibor Csőszi, Andrea Fülöp,[...]. N Engl J Med 2018
8

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi,[...]. N Engl J Med 2018
8

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
239
8

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Zachary R Chalmers, Caitlin F Connelly, David Fabrizio, Laurie Gay, Siraj M Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki,[...]. Genome Med 2017
8

The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer.
Hye Ryun Kim, Su-Myeong Park, Sang-Uk Seo, Inkyung Jung, Hong In Yoon, Dmitry I Gabrilovich, Byoung Chul Cho, Seung-Yong Seong, Sang-Jun Ha, Je-In Youn. Am J Respir Crit Care Med 2019
35
11

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Laura Mezquita, Edouard Auclin, Roberto Ferrara, Melinda Charrier, Jordi Remon, David Planchard, Santiago Ponce, Luis Paz Ares, Laura Leroy, Clarisse Audigier-Valette,[...]. JAMA Oncol 2018
292
8

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.
Nicolas Guibert, Greg Jones, John F Beeler, Vincent Plagnol, Clive Morris, Jean Mourlanette, Myriam Delaunay, Laura Keller, Isabelle Rouquette, Gilles Favre,[...]. Lung Cancer 2019
31
12

Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Yusuke Okuma, Hiroshi Wakui, Hirofumi Utsumi, Yukiko Sagawa, Yukio Hosomi, Kazuyoshi Kuwano, Sadamu Homma. Clin Lung Cancer 2018
51
8

Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study.
L Cabel, F Riva, V Servois, A Livartowski, C Daniel, A Rampanou, O Lantz, E Romano, M Milder, B Buecher,[...]. Ann Oncol 2017
129
8

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Shirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, Emilio Esteban, Enriqueta Felip, Manuel Dómine, Rina Hui, Maximilian J Hochmair, Philip Clingan, Steven F Powell,[...]. J Clin Oncol 2020
158
8

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
8

Cancer immunoediting and resistance to T cell-based immunotherapy.
Jake S O'Donnell, Michele W L Teng, Mark J Smyth. Nat Rev Clin Oncol 2019
336
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.